IN8BIO INC. - COMMON
0.2550
07-10月-24 15:59:48
15 分の遅延
株式
-0.0083
-3.15%
本日の幅
0.2402 - 0.2760
ISIN
N/A
ソース
NASDAQ
-
08 12 2022 07:00:00 提供 Nasdaq GlobeNewswire
-
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
10 11 2022 07:30:01 提供 Nasdaq GlobeNewswire
-
03 11 2022 09:10:00 提供 Nasdaq GlobeNewswire
-
IN8bio to Present at November Investor Conferences
01 11 2022 07:30:00 提供 Nasdaq GlobeNewswire
-
IN8bio to Present at Cantor Oncology & HemOnc Conference
27 9 2022 07:30:00 提供 Nasdaq GlobeNewswire
-
15 9 2022 07:30:00 提供 Nasdaq GlobeNewswire
-
IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
13 9 2022 07:30:00 提供 Nasdaq GlobeNewswire
-
IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board
08 9 2022 07:30:00 提供 Nasdaq GlobeNewswire
-
IN8bio to Present at September Investor and Scientific Conferences
30 8 2022 16:15:00 提供 Nasdaq GlobeNewswire
-
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
19 8 2022 09:20:47 提供 Nasdaq GlobeNewswire
-
IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock
16 8 2022 16:15:00 提供 Nasdaq GlobeNewswire
-
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
12 8 2022 16:15:00 提供 Nasdaq GlobeNewswire
-
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock
11 8 2022 22:05:00 提供 Nasdaq GlobeNewswire
-
27 7 2022 07:00:01 提供 Nasdaq GlobeNewswire
-
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform
21 7 2022 07:00:01 提供 Nasdaq GlobeNewswire
-
IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development
12 7 2022 08:00:01 提供 Nasdaq GlobeNewswire
-
IN8bio to Present at July Investor and Scientific Conferences
30 6 2022 16:15:00 提供 Nasdaq GlobeNewswire
-
08 6 2022 08:00:01 提供 Nasdaq GlobeNewswire
-
06 6 2022 07:00:00 提供 Nasdaq GlobeNewswire
-
17 5 2022 07:00:02 提供 Nasdaq GlobeNewswire